# Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

> **NCT00432172** · PHASE2 · COMPLETED · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 189 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel
- **DRUG:** Exemestane
- **DRUG:** Goserelin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00432172
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04-24
- **Primary completion:** 2010-09-01
- **Final completion:** 2010-09-01
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2023-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00432172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00432172, "Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00432172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*